Skip to main content

Table 1 Logistic multivariate regression results

From: Detection of statin-induced rhabdomyolysis and muscular related adverse events through data mining technique

Variables OR SE z P-value 95% CI
Intercept 0.000 0.000 − 13.160  < 0.001* (0.000, 0.000)
Statin groups
0. Low-dose hydrophilic 1.000
1. High-dose hydrophilic 0.811 0.565 − 0.300 0.763 (0.207, 3.177)
2. Low-dose lipophilic 0.743 0.306 − 0.720 0.470 (0.331, 1.664)
3. High-dose lipophilic 1.227 0.523 0.480 0.630 (0.533, 2.829)
Medications
Antifungals 2.865 2.095 1.440 0.150 (0.683, 12.008)
Clarithromycin 2.777 1.297 2.190 0.029* (1.112, 6.934)
Ticagrelor 2.220 1.344 1.320 0.188 (0.678, 7.271)
Cyclosporine 2.127 1.306 1.230 0.219 (0.638, 7.089)
Carvedilol 1.534 0.442 1.490 0.138 (0.872, 2.697)
Colchicine 1.327 0.459 0.820 0.413 (0.674, 2.613)
Amiodarone 0.654 0.319 − 0.870 0.384 (0.251, 1.703)
Digoxin 0.594 0.441 − 0.700 0.483 (0.138, 2.549)
Diltiazem 0.865 0.451 − 0.280 0.781 (0.311, 2.405)
Ezetimibe 0.712 0.256 − 0.950 0.344 (0.352, 1.439)
Ciprofloxacin 0.419 0.196 − 1.860 0.063 (0.167, 1.049)
Gemfibrozil 0.508 0.513 − 0.670 0.503 (0.070, 3.674)
Other covariables
AST (> 30 U/L) 35.294 20.824 6.040  < 0.001* (11.104, 112.181)
eGFR (< 60 mL/min/1.73 m2) 2.360 0.617 3.280 0.001* (1.413, 3.940)
Hypertension 1.774 0.504 2.020 0.044* (1.017, 3.095)
Age (> 65 years old) 0.640 0.157 − 1.820 0.069 (0.396, 1.036)
LDL (> 125 mg/dL) 0.409 0.122 − 3.010 0.003* (0.228, 0.733)
Variables Odds Ratio Std. Err z P-value 95% CI
Interaction effects of high-dose lipophilic statin
 + Clarithromycin 5.662 4.908 2.000 0.046* (1.035, 30.962)
 + Antifungals 5.840 6.071 1.700 0.090 (0.761, 44.796)
 + Clarithromycin
 + Antifungals
16.219 18.309 2.470 0.014* (1.775, 148.226)
 + Ticagrelor 4.526 4.256 1.610 0.108 (0.717, 28.584)
 + Cyclosporine 4.337 4.157 1.530 0.126 (0.662, 28.389)
 + Carvedilol 3.127 2.430 1.470 0.142 (0.681, 14.344)
 + Colchicine 2.705 2.180 1.230 0.217 (0.558, 13.125)
  1. * p < 0.05